Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (September 2016)
41 slides from Sorrento Therapeutics's investor presentation, Sep 22, 2016
Slide 1: Corporate September Presentation 2016
Exhibit 99.1 Exhibit 99.1 Corporate SCINTILLA September Presentation 2016
Slide 2: Disclaimer
Scintilla Disclaimer Nasdaq presenting to future Statements FDA’s collaboration Pharmaceuticals, product The in Because NASDAQ:SRNE any (“SEC”) its Scintilla™, 2All SCINTILLA Logo—http://photos.prnewswire.com/prnh/20150105/167173LOGO historic the business other forward-looking Company Company’s oper
Slide 3: Company Overview
a Ss Company Overview
Slide 4: Our Vision and Mission
Vision SCINTILLA Our To 4patient significantly develop Vision Mission and and Mission healthcare and commercialize advance system treatments needs a newand generation outcomesoffor pain pain medications patients with targeting innovative, moderate non-opioid to severe pain pain management with impro
Slide 5: Scintilla Portfolio Overview of Pain Product Candidates
Scintilla Portfolio Pain SP-102: 5–RTX: Sorrento SCINTILLA Pharmaceuticals Semnur INDSpectrum Projected Phase Cancer Scheduled Orphan afiling novel 1first Overview Pharmaceuticals of Pain Drug / 2to Two to target non-opioid, trial clinical non-opioid begin IND begin Designation Investigational inin
Slide 6: Investment Highlights
Investment Innovative, Worldwide Strong Two 6Current Sorrento Products Proprietary Standard Commercial Highlights Non-opioid withofPlatform Blockbuster CarePain Rights with Management to Potential High All Product Barriers Poised Portfolio Candidates totoEntry Replace Large, Established Established,
Slide 7: The Right Team to Deliver Long-Term Value
TheClinical, 25+ Henry Jaisim CEO, 20+ Dmitri VP Glen Legal Suketu Chief 7Bryan Right years Sato, Technology Medical Sorrento Semnur /Jones, Ji, Shah Lissin, Desai, Interim PhD of Team JDChief Xenoport; research clinical PhD PhD Pharma; MD Chairman Officer Therapeutics Chief to 20+ Officer VP, Execu
Slide 8: Chronic Pain Market Landscape
TheASIPP, Costs Nearly Greater Growing High Myriad Not Acute Pain Chronic Scintilla (1) http://www.aana.com/newsandjournal/documents/snarr183-188.pdf; (3) Decisions suitable Pain likely rate the Chronic 30 of than pain Non-Malignant Focuses Focus government, Market United of million serious NIH, a a
Slide 9: Pipeline Opportunity and Development Milestones
Strong Market Positioning Development Potentially –SP-102 Progressive No Phase Novel RTX Novel Non-particulate, of Morecurrently 1non-opioid $2.3 would Lema 9NEJM Pipeline Opportunity than et /gel al2billion(1) allow July the single trial formulation disease approved 80% 2011Milestones first with in
Slide 10: Significant Near-Term Clinical Milestones
Significant –Multiple In Program Period SP-102 Complete IND Phase RTX 10 Start Results Mid addition, and Phase 1to 2H Phase / 2016 clinical late 2Results 1H Phase Near 1potential stage /32H 2017 2Start Phase Term milestones 31H trials 2018 corporate Phase 2H Clinical 2 commencing 3forMilestone devel
Slide 11: SP-102: Innovative Non-opioid Injectable for Chronic Pain
SP-102: Innovative Non-opioid Injectable for Chronic Pain 11
Slide 12: SP-102 Program Profile
Lowlong-term Market Unsatisfied Very Program Development Shortened Risk Response Novel Large Profile Familiarity Positive SP-102 No Preclinical Scheduled Physicians 12 interventional Technical Positive Growing number SP-102 Chronic profile FDA toto and see and begin systemic PIND of an targeted Phas
Slide 13: FDA Communication and Development Plan
FDA treated is –Communication Agree Need Pediatric Safety Primary dependent Pre-IND expressed focus with bridging to Follow-Up endpoint 505(b)2 Study on 3on –local Meeting interest 6tox regarding (comparative Plan injections/year; application at study tox; – 4“6 needed (2014) in weeks, did month and
Slide 14: Fungal Meningitis Outbreak Caused by Compounding Pharmacy
Fungal THE 04.24.2016. Newsweek A INSIDE Meningitis CASE MURDER MASS Infected By 14MEDICAL Kurt KILLER Meningitis Eichenwald more outbreak than PHARMACY Outbreak 800 caused / April people by 16, (2012-14) across compounding 2015, 20 http://www.newsweek.com/2015/04/24/inside-one-most-murderous-corpor
Slide 15: Epidural Steroid Injections Are Common
0Common CDC, http://updates.pain-to Medicare Key Epidural increased 152,500 Points HCUP, 5,000 Steroid steroid Surgical 130% Overall Scintilla 7,500 per injections Injections ESI Procedures 100,000 10,000 pics.org/2012/01/epidural-steroid-injections.html, Injection dataare (ESIs) 10,000 onMedicare i
Slide 16: SP-102 Market Epidemiology
SP-102 Spinal Large Disc Degenerative Occasional Surgically Pain Frequent Lumbosacral Significant Inconsistent Undefined Chronic Epidemiology Patients –Lumbar If Source: *Stafford 2007.http://www.aana.com/newsandjournal/documents/snarr183-188.pdf. 16 Age Spinal Disc Imaging Some Patient 116 27% Comm
Slide 17: Current Multi-Modal Management of Back Pain
A Focus Current Multi-Modal Management Potential SP-102 “Consultants, — 1. 2. 3. 17 Academy Prescription back Multi-modal Multiple Efficacy, Practice American pain2 Problem on for radiculopathy Guidelines medical Center Tolerability Non-narcotic ofSociety Pain ASA opioid Orthopedic The analgesia the
Slide 18: Current Steroid Formulation Safety Issues
Chronic Steroid Used Less Drug Methylprednisolone Depomedrol Kenalog Betamethasone Soluspan Contains Dexamethasone Decadron of AllThe alcohol• •EDTA• corticosteroids marketed current Neurotoxicity Benzyl safety Formulation Currently Injections Back benzyl benzalkonium Neurotoxicity •Benzyl ESI alcoh
Slide 19: SP-102 Important Product Attributes
SP-102 Important (Potential) FDA-approved radicular Clinical efficacy Fast spread Duration Reduction Safer Lower Novel residency No Prefilled Depo-Medrol olone) Surfactants Preservatives Particulates onset repeat formulation risk Differentiated data Syringe pain of ———— KenalogCelestone time Treatme
Slide 20: Physicians Favorability of SP-102
SP-102 Physicians Overall with revenue “It’s 7Steroid 6.3 Anesthesiologists Specialty “Cost — 20 Anesthesiologist 6novel a6.1 543210 may 6,A’s Clinical Reaction caused and 6.36.2 Group and be reacted stated Favorability four high, disruptive. by Utility duration PMR with lower favorably but 5of ifSp
Slide 21: Lifecycle Upside Opportunities
Lifecycle Physicians LR Forecast 8.3 5.5 Non-LR ~50-200%* Additional Carpel Trigger Injections Cervical Knee Hip Complex Lumbar Acute Discogenic *Assumes 21 –Procedure Mand 16.5 Arthritis Spinal Non-LR Tunnel Point Spinal Knee Procedure Radiculopathy 5.5 Regional Management for Msimilar Uses indicat
Slide 22: SP-102 Toxicology Program Design
SP-102 Identical Multiple mg SD Multi-dose 22 in Epidural Intrathecal 10.4 Toxicology mL arm programs mL epidural Control Placebo Low Med High GLP control low Med high dose: dose: study in dose Program dose Dose control med (saline) 0.4 1 >100 (saline) mLusing dose mLBeagle (once Design 1(once 2mL r
Slide 23: SP-102 Additional Preclinical Study Results
SP-102 Hydrodynamic Addition Decadron) commercial Toxicology No stains, –Additional 23Placebo Direct Nodrug-related toxicity: NOAEL Preclinical injection ofarm have Vascular Studies viscosity products, vessel clean Study isan toxicity, into highest Study epidural Completed tox –occlusion agent Resul
Slide 24: SP-102 Corporate and Clinical Development Plan
SP-102 Corporate –Stage 24 Adequate Open-label, Phase Pediatric 1:Clinical 2: 31Commercial IND /Clinical open study 2and trial to long-term label well-controlled pivotal Development (plan inStrategy chronic safety scale-up toPhase safety request study isback based 3Plan decision study Phase efficacy
Slide 25: SP-102 Projected Clinical Development: Phase 1/2
SP-102 An Sodium Injection Interim –Projected 25 Avoid CT-guidance Contain Enrollment LPLV CSR Open-label, delivered Analysis Clinical Phosphate dilution October indrug Subjects completion in Single-arm, Development: (no January 2016 completed epidural Injection, contrast, with2017 September Lumbar
Slide 26: SP-102 Clinical Development: Phase 3 C.L.E.A.R.
SP-102 Corticosteroid Evaluate lumbosacral –analgesic 26Lumbosacral Clinical Leg pain Clinical the effect symptoms ( 5, radiculopathy analgesic Lumbar 9) Radicular Evaluate Development: present consistent effect Epidural the for Pain Evaluate safety on atSelection C.L.E.A.R. least with leg Analgesia
Slide 27: High Barriers to Entry and Intellectual Property
High Intellectual Filed Provisional U.S. Barriers –Generics 27 Trade UseApplication Long Patents FDAProvisional Barriers IP ofrequirement term secrets, filing to specific claiming Competition Property Application Supply to claiming substantial Entry Application No. excipient proprietary for and 14/1
Slide 28: RTX: First-in-class Therapeutic for Intractable Pain
RTX: First-in-class Intractable 28 Pain Therapeutic for
Slide 29: RTX Product Overview and Mechanism of Action
Product Ultra Scoville –Action Pharmacological Potentially Safety No Targeted Patient 29Jalapeno Dorsal effect potent Alteration 2-5000 need Overview: units horn single onpermanent TRPV1 not normal = injection >discontinue sequence of 12,000 RTX heat acute agonist clinically sensation for times pain
Slide 30: RTX Intractable Cancer Pain Epidemiology
RTX Intractable M 80% WHO 1. Van Ross Datamonitor Estimated –Cancer 18 53% 33% NIH Cancer Moderate den million of Cancer etestimates or /Pain cancer al. Beuken-van NCI about Prevalence Pain Patients 20006 cancer Americans –Pain December and Severe patients 10 3.1 10and Scintilla Epidemiology pain mi
Slide 31: RTX Application Beyond Cancer Pain
RTX Cancer Tissue Focal Neurogenic Syndromes Inflammation Organ Pain and –Cardiac myocardial Trigeminal Post Chronic Cardiac Heart PAfferent Breaks substance Neuropathies Herpetic failure Injury Pain is Application sympathetic innervated Pancreatitis ischemia –Neurogenic Inflammation Nerve Phantom C
Slide 32: RTX Preclinical Canine Bone Cancer Data
RTX Preclinical Permanent Or Could (0 No Fully Return Reported Source: 60 Score 40 Pain Observational 30 010 32 Weeks 2VAS p=0.0001 n=18 High Side Loss 6for POC: 10 Alert 50 Sense Of Brown all Effects 14 Dose n=8 Of By “Normal” Findings Reduction Post-treatment Canine time Muscle Normal Owners n=5 2
Slide 33: First-in-Human Study Overview and Results
First Study A FIH Pain 12 Placed Pharmacy Improved No 3MTD Reduced (1) non- Phase patients ClinicalTrials.gov unexpected Open-label, in In-Human not Overview or on refractory 1Opiate poorly-ambulatory reached pain clinical failed Study haveand toxicities Study Usage been an Results dose ofcancer wit
Slide 34: Epidural vs Intrathecal Injection
SwitchGreen Epidural Intrathecal Note: Untreated 34 toinjection Epidural Intrathecal injection = Substance into into Epidural orthe P near ascerebrospinal marker the dorsal of Afferent root fluid ganglion space nerves. (CSF) (DRG)targeting for unilateral both DRGs or diffuse and pain dorsal horn neu
Slide 35: RTX Regulatory, Clinical and CMC Status
Human GMP Mutagenicity Lumbar Tox Cancer Preclinical Cardiovascular Clinical, –Regulatory INDAPI Epidural Mini 2nd Pre-IND Hypertension planned Pig Pain Program GLP completed MED meeting & study completed, studies early Status study at with UCLA Model 2017 (3 completed 2017 registration Cardio Patho
Slide 36: Current Cost of Uncontrolled Cancer Pain
Current Estimated Year Pump 6Per Top Fever (N=1,351) Sepsis Uncontrolled Dehydration Pneumonia Admission Total *Source: Publication.2000, ** 36Month Month 5Assuming Cost Reasons Rental, 2000Today** Treatment MSA 15% ** treatment Cost of Cost The Assuming Uncontrolled $4,625$6,845 Pain Internal medic
Slide 37: Market Research on Pricing and Payer Coverage
Market Initial Our Based Current access clinical “comfort (1) 37 Study evaluation Price on for Research(1) profile coverage zone” Key approved effective Point Study and suggests considering ofresults pain by comparator Findings Scintilla that management with the theRTX and cost therapies market prep
Slide 38: RTX Marketing Opportunities
RTX Inadequate Opportunities Innovative, –potential nausea, With Marketing long-term vomiting competitive treatment non-opioid, Opportunities and use,for cost constipation. opioids non-addictive cancer advantage gradually patients Inover addition, analgesic lose with opioids their intractable for th
Slide 39: Significant Near-Term Clinical Milestones
Significant –Multiple In Program Period Phase SP-102 Complete RTX 39Mid IND StartResults addition, 1toand Phase /2H clinical late 2Phase 2016 Near Phase potential Results 1H2H1H2H Phase stage 1 /20172018 3Term milestones 21Start trials Phase 3/ 2corporate Clinical Phase commencing 2 for3Milestones d
Slide 40: Financing: Private Placement and Use of Proceeds
Financing –~$100 Fundhires Pipeline Key Commercial Payment General Mclinical Private corporate and additions toacross shareholders launch Use trials Placement departments ofpurposes and Proceeds prepNDA related of Common submissions to Semnur Stock acquisition
Slide 41: Investment Highlights
Investment Innovative, Worldwide Strong Two Current 41 Products Proprietary Standard Commercial Highlights Non-opioid withofPlatform Blockbuster CarePain Rights with Management to Potential High All Product Barriers Poised Portfolio Candidates totoEntry Replace Large, Established Established, Reimbu
Sorrento Therapeutics — Investor Presentation (September 2016) on 6ix